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SUMMARY 
Objective: Preliminary evidence suggests that serotonin reuptake inhibitor (SRI) use may 
increase postictal respiratory drive and prevent death. We sought to determine whether 
SRIs are associated with improved all-cause and possible seizure-specific mortality in 
patients with epilepsy. 
Methods: Patients with epilepsy and a random 10:1 sample without epilepsy were 
extracted from The ClinicAl Research using LInked Bespoke studies and Electronic health 
Records (CALIBER) resource. The hazard ratio (HR) of all-cause and possible seizure-
specific mortality, treating SRI use as a time varying covariate, was determined using the 
date of a second SRI prescription as exposure and in discrete 6-month periods over the 
entire duration of follow-up. We used Cox regression and competing risk models with 
Firth correction to calculate the HR. We controlled for age, sex, depression, comorbidity 
(Charlson comorbidity index) and socioeconomic status (Index of Multiple Deprivation).   
Results: We identified 2,718,952 eligible patients in CALIBER of whom 16,379 (0.60%) 
had epilepsy. Median age and follow-up were 44 (interquartile range [IQR] 29-61]) and 
6.4 years (IQR 2.4-10.4 years) respectively and 53% were female.  A total of 2178 
patients (13%) had at least two SRI prescriptions. Hazard of all-cause mortality was 
significantly elevated following a second prescription for an SRI ([HR 1.64 95% 
confidence interval [95%CI] 1.44-1.86; p<0.001). The HR was similar in 163,778 age, sex, 
and GP practice matched controls without epilepsy. Exposure to an SRI was not 
associated with seizure-related death (HR 1.08, 95%CI 0.59-1.97; 0.796).    
Significance: There is no evidence in this large population-based cohort that SRIs protect 
against all-cause mortality or seizure-specific mortality. Rather, SRI use was associated 
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with increased mortality, irrespective of epilepsy, which is probably due to various 
factors associated with the use of antidepressants. Larger studies with systematically 
collected clinical data are needed to shed further light on these findings.  
Key words: Linked electronic medical records, cohort study, all-cause mortality, seizure-
specific mortality, antidepressants, epidemiology 
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KEY POINTS 
1) Serotonin reuptake inhibitors have been associated with increased respiratory 
drive in the postictal state. 
2) Clinical need for a serotonin reuptake inhibitor is associated with increased all-
cause mortality in patients with and without epilepsy 
3) Clinical need for a serotonin reuptake inhibitor is not associated with seizure-
related mortality in this large population-based cohort.  
4) Presumed use of serotonin reuptake inhibitors does not appear to be acutely 
associated with all-cause mortality  
5) RCTs of serotonin reuptake inhibitor use for mortality in epilepsy are impractical; 
linked electronic health data provide an alternative  
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INTRODUCTION 
Premature mortality in epilepsy is a major concern facing general practitioners, 
neurologists, and epileptologists alike. The estimated standardized mortality ratio for 
those with epilepsy is 2.2 fold higher than that for people without epilepsy1. Hence, 
interventions designed to reduce all-cause premature mortality are of intense interest.  
 
In addition, sudden unexpected death in epilepsy (SUDEP) is a specific cause of death 
and a major health concern for people with epilepsy. It is defined as a sudden, 
unexpected, non-traumatic, and non-drowning death of a patient with epilepsy with no 
post-mortem evidence of a structural or toxicological cause for death2. Based on this 
working definition, sudden unexpected death is almost 24 times more likely in selected 
populations with epilepsy compared to the general population (standardised mortality 
ratio 23.7, 95% confidence interval [95%CI] 7.7 to 55.0)3. Estimates of SUDEP incidence 
range from 0.09 to 9.3 per 1000 person-years depending on the severity of epilepsy4.  
 
The pathological processes leading to seizure-related deaths and, specifically to SUDEP, 
remain elusive. Post-ictal respiratory depression, cardiac arrhythmias, and 
electrocerebral suppression may contribute to the increased risk of death4, 5. Serotonin 
reuptake inhibitors (SRIs) may have particular promise as a therapeutic intervention 
since they increase mental vigilance, promote respiratory activity, and may prevent 
sudden death6. Reductions in ictal respiratory arrest with SRIs and increased respiratory 
depression with the serotonin antagonist cyproheptadine have been demonstrated 
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using murine models7, 8. Furthermore, a reduction in ictal-related oxygen desaturations 
in focal seizures without bilateral convulsions has been reported in patients taking SRIs 
admitted to seizure monitoring units9.  
 
There has therefore been interest in exploring the therapeutic role of SRIs as a means of 
reducing premature mortality, especially for patients at high risk of SUDEP10. However, 
to date, no large-scale studies in humans have been performed to either confirm or 
refute this potential indication. We carried out an observational study using large, pre-
existing linked primary care data in England collected during routine clinical practice to 
examine the association between SRI use and mortality in patients with epilepsy. 
 
METHODS 
The ClinicAl Research using LInked Bespoke studies and Electronic health Records 
(CALIBER) resource (https://www.ucl.ac.uk/health-informatics/caliber)11 contains 
United Kingdom (UK) nationally linked structured electronic health records (EHR) data 
from primary care, hospital care, and a cause-specific mortality registry between 
January 1, 1997 and March 31, 2010. We only followed patients enrolled from January 
1, 1997 to March 31, 2009 to account for an up to one-year lag in mortality reporting.  
 
The platform contains pseudonymised health records of 2,718,952 eligible adult 
patients. Primary care diagnostic data are recorded using Read codes12. Prescription 
data are recorded by the general practitioner and classified according to the British 
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National Formulary13, 14. Audit nurses and professional clinical coders are employed to 
abstract secondary care and administrative data into the Hospital Episode Statistics 
database. Diagnoses and procedures coded in the affiliated databases use the 
International Classification of Diseases (ICD) and the Office of Population Censuses and 
Surveys Classification of Interventions and Procedures terminology. Cause-specific 
mortality data are acquired from death certificates and categorised using the ICD-9 and 
-10 terminologies at the UK Office for National Statistics.  
 
Study population 
We used a published epilepsy case definition designed specifically for Clinical Practice 
Research Datalink (CPRD) EHR platforms15. This definition requires a single Read code 
for an epilepsy syndrome or two Read codes for symptoms of epilepsy (i.e. codes for 
non-febrile seizures on two or more occasions) and two anti-epileptic drug codes within 
4 months. The definition is 92% accurate for detecting cases of paediatric epilepsy15 
and, after review by two adult epileptologists (CBJ and SW), is expected to perform 
comparably well in adult populations. We ultimately compared the prevalence to that of 
the UK population as a means of establish face validity the epilepsy cohort16.  
 
All patients aged 18 years or greater at epilepsy diagnosis, registered in CPRD practices 
in England, with at least 1 year of up-to-standard pre-study follow-up during which the 
patient was not prescribed an SRI (paroxetine, fluoxetine, fluvoxamine, sertraline, 
citalopram, escitalopram) were included in the analysis. The up-to-standard designation 
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is provided by CPRD following regular quality checks and practices in each GP surgery. 




The index date was that on which the patient met the case definition for epilepsy. The 
index date was 1-year post up-to-standard date in those without epilepsy (who were 
matched on age, sex, and GP practice). Parametric and non-parametric descriptive 
statistics were used to compare populations of interest. We calculated mortality 
incidence rates for the epilepsy and control populations as a whole and stratified by SRI 
use.  
 
Multiple independent analyses were used to evaluate the association between SRI use 
and mortality. First, we treated SRI prescriptions as time-varying covariates. To exclude 
trivial exposures, a patient was considered unexposed until their second SRI 
prescription. On this date, their status transitioned from unexposed to exposed, and 
they maintained this designation until the end of follow-up.  
 
We cannot ensure an enduring exposure through this approach and therefore, to 
mitigate this concern, we performed a second time-varying Cox-proportional hazards 
regression analysis in which we stratified follow-up into discrete 6-month epochs to 
more firmly establish any temporal association between SRI prescription and death. In 
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this time-varying analysis, exposure to an SRI prescription was recorded as a 
dichotomous (‘yes’/’no') variable during each epoch, based on the presence or absence 
of a prescription code during that time period. We then coded each patient as having 
lived (‘0’) or died (‘1’) during that same epoch.  
 
The primary outcome was all-cause mortality. The secondary outcome was possible 
seizure-related death (under which SUDEP would fall) as defined by selected ICD-10 
codes from epilepsy/seizures/convulsions, unknown/unspecified death, and sudden 
death diagnostic categories (Appendix 1). In addition to time-varying SRI status, we also 
controlled for baseline age, sex, past or current depression (using an electronic health 
records phenotype defined in a prior CALIBER study17), comorbidity using the Charlson 
comorbidity index (CCI) and for socioeconomic status with the Index of Multiple 
Deprivation (IMD), a measure of relative deprivation in 32,844 localised regions of 
England (1 being the most deprived and 32,844 being the least deprived)18. In a separate 
analysis, we also included an interaction term between sex and second SRI prescription 
exposure to investigate any putative sex-specific effect. In each analysis, patients were 
censored at the end of the follow-up if no outcome occurred or they were lost to follow-
up. 
 
We considered a p-value of ≤0.05 to be statistically significant. We used cause-specific 
Cox regression and the Fine and Gray competing risks models19 that used a Firth 
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We randomly identified exact age, sex, and general practitioner (GP) practice matched 
control patients without epilepsy in a 10:1 ratio using MySQL 5.721. The algorithm 
identifies potential matches and orders them randomly by assigning a random seed. 
Checks are then instituted to ensure minimum follow-up, concordant observation 
periods, and up-to-standard data. All aforementioned analyses were replicated in this 
control cohort to determine if the association between SRI use and mortality is unique 
to patients with epilepsy or common to the general population. 
 
Finally, we performed a sensitivity analysis in which we evaluated the risk of all-cause 
death and possible seizure-related death, using the analysis plan described above, 
following a second prescription for bupropion. This is a unique antidepressant that does 
not modulate the serotonin system. Thus, we aimed to determine whether any putative 
association between prescription coding and death was serotonin-specific or related to 
antidepressant use in general.  
 
Software 
All analyses were conducted using Stata version 13.122, R23, and SAS® software24.   
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Approvals and governance 
CALIBER is registered with the University College London Data Protection Office 
(Z6364106/2009/2/26). Scientific Approval for this study was obtained through the 
Independent Scientific Advisory Committee (ISAC) Evaluation of Protocols For Research 
Involving CPRD Data process (protocol number 15_215R2).  
 
RESULTS 
We identified 2,718,952 patients in CALIBER of whom 16,379 (0.60%) met the case 
definition for epilepsy. Median age was 44 years (interquartile range [IQR] 29-61) and 
8610 (53%) were female. Median follow-up was 6.4 years (IQR 2.4-10.4 years). For basic 
descriptive statistics, we considered exposure to two or more SRIs prescriptions as 
meaningful. According to this definition, 2178 patients with epilepsy (13%) received an 
SRI. Patients receiving two SRI prescriptions differed from those receiving one or no 
prescription on a number of demographic indices in directions anticipated from clinical 
experience (Table 1).  
 
SRI exposure and all-cause mortality 
The unadjusted incidence rate of all-cause mortality was approximately two-fold higher 
for those with epilepsy (n=16,379; incidence rate = 0.024 [2524 deaths/105644.1 
person-years]) compared to those without (n=163, 778; incidence rate = 0.012 [14523 
deaths/1196841 person-years]). Exposure to a second SRI prescription was associated 
with an increased mortality rate in both those with epilepsy (0.035 [337 
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deaths/9766.809 person-years] versus 0.023 [2187 deaths/95877.27 person-years] in 
those unexposed; incidence rate ratio [IRR] = 1.51) and in the general population (0.021 
[1587 deaths/77243.51 person-years versus 0.012 [12936 deaths/1119597 person-
years] in those unexposed; IRR = 1.79). 
 
Exposure to a second SRI prescription was associated with an increased hazard of death 
(hazard ratio (HR) 1.64, 95%CI 1.44-1.86; p<0.001) in those with epilepsy. Additional 
associations with all cause death were noted for age (HR 1.06 for each increment in age, 
95%CI 1.06-1.07), female sex (HR 0.78, 95%CI 0.72-0.85; p<0.001), and IMD score (HR 
1.01, 95%CI 1.01-1.01; p<0.001; Table 2, Figure 1). There was no sex-specific effect of a 
second SRI prescription on premature mortality when an interaction term was included 
in the regression model (sex by SRI prescription HR = 0.87, 95%CI 0.69-1.10; p=0.252).   
 
Exposure to a single SRI prescription was associated with a statistically significant 
increased hazard of death within 6-months (hazard ratio [HR] 1.04, 95%CI 1.00-1.09, 
p=0.04; Table 3) when controlling for age, sex, CCI, IMD, and depression in those with 
epilepsy. In addition, the hazard of death was elevated for each one-year increment in 
age (HR 1.06, 95%CI 1.06-1.07; p<0.001), and each incremental one-rank increase in 
social deprivation (HR 1.01, 1.01-1.01; p<0.001). Female sex was protective (HR 0.76, 
95%CI 0.70-0.83; p<0.001; Table 3).  
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The hazard ratio of all-cause death was similarly elevated for 163,778 age, sex, and GP 
practice matched controls without epilepsy. Those exposed to a second SRI prescription 
had an increased risk of all-cause death (HR 2.07, 95%CI 1.95-2.20; p<0.001; Table e-1) 
when controlling for age, sex, depression, CCI, and IMD.  Increasing age (HR 1.10 for 
each incremental year, 95%CI 1.09-1.10; p<0.001) and increasing social deprivation (HR 
1.01, 95%CI 1.01-1.01; p<0.001) were also independently associated with all-cause 
mortality whilst female sex was associated with a significantly decreased risk (HR 0.69, 
95%CI 0.67-0.72; p<0.001). When evaluated in 6-month epochs, the hazard of death in 
the general population without epilepsy was not significantly elevated for those taking 
an SRI compared to the unexposed (HR 1.00, 95%CI 0.98-1.02; p=0.74) when controlling 
for age, sex, CCI, depression, and IMD (Table e-2).  
 
 
SRI exposure and possible seizure-related mortality 
The unadjusted incidence rate of possible seizure-specific mortality was roughly 
equivalent for those with epilepsy exposed to two or more SRI prescriptions (incidence 
rate = 0.0013 [13 deaths/9766.8 person-years]) compared to those exposed to one or 
no SRI prescriptions (incidence rate = 0.0014 [138 deaths/95877.3 person-years]).  
 
Using a cause-specific Cox regression model, there was no significant difference in 
possible seizure-related mortality according to time-varying SRI exposure (HR 1.08, 
95%CI 0.59-1.98; p=0.80) in the epilepsy population though female sex was protective 
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(HR 0.70, 95%CI 0.50-0.96; p=0.03; Table 4). The estimate was imprecise due to few 
outcomes. Likewise, using a competing risks model with a Firth correction, the hazard of 
a possible seizure-related death within 6-months of prescription was not significantly 
elevated (HR 1.04, 95%CI 0.91-1.20; p=0.51). Each 1-year increment increase in age was 
associated with an elevated risk of possible seizure-related death, as was each one-point 
increase in CCI and with worsening IMD. Female sex was, again, protective (Table e-3) 
 
Bupropion exposure and mortality 
We identified 15 (0.10%) patients exposed to two or more prescriptions for bupropion 
in the epilepsy cohort. The hazard of all-cause death was not significantly higher if 
exposed (HR 1.91, 95%CI 0.61-5.93; p=0.26) though the overall estimate was imprecise 
due to the low number of outcomes (5 deaths over 74.8 person-years in the bupropion 
group compared to 2517 deaths over 105,569.3 person-years in the unexposed group). 
Insufficient numbers were available to evaluate the hazard of possible seizure-related 
mortality (0 possible seizure-related deaths over 74.8 person-years in those exposed to 
two or more bupropion prescriptions compared to 151 possible seizure-related deaths 
over 105,569.3 person-years in those exposed to one or no bupropion prescription). 
 
We identified 685 of 163,778 (0.42%), who received two bupropion prescriptions in the 
age, sex, and GP practice matched general population without epilepsy. Of those 
receiving two bupropion prescriptions, 296 (43%) had a code for current or past 
depression. Interestingly, unlike the SRI analysis, the unadjusted mortality rate for those 
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exposed to two or more bupropion prescriptions (incidence rate of all-cause death = 
0.012 [43 deaths/3599 person-years]) did not appear to differ substantially from those 
exposed to one or no prescription (incidence rate = 0.012 [14480 deaths/1,193,242 
person-years). However, bupropion is not approved for depression or anxiety in the UK 
(only for smoking cessation) and therefore we were concerned that there may be an age 
discrepancy between the two groups. Those unexposed to two or more bupropion 
prescriptions were significantly older (median age 42; range 17-88) than those exposed 
(median age 40, range 18-69; p = 0.02) thus indicating a potential confounding 
protective effect. Indeed, when adjusting for age, the HR of death was twice that for the 
exposed compared to unexposed (HR 2.06, 95%CI 1.52-2.81; p <0.001)  
 
Similar to the SRI analyses, the adjusted hazard of all-cause mortality (when controlling 
for age, sex, depression, CCI, and IMD) was significantly higher for those exposed to two 
or more bupropion prescriptions (HR 1.95, 95%CI 1.44-2.66; p<0.001).  Increasing age 
(HR 1.10 for each incremental year, 95%CI 1.09-1.10; p<0.001), current or past 
depression (HR 1.19, 95%CI 1.15-1.24; p<0.001), and increasing social deprivation (HR 
1.01, 95%CI 1.01-1.01; p<0.001) were all independently associated with all-cause 
mortality. Female sex conversely was associated with a significant protective effect (HR 
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DISCUSSION 
This study using large, linked data collected during the course of routine care has 
paradoxically demonstrated that, contrary to evidence yielded from animal models, SRI 
use in patients with active epilepsy is associated with an elevated, rather than a 
decreased, risk of mortality. However, the risk appears generalisable to the overall 
population as similar results were seen in age, sex, and GP practice-matched patients 
without epilepsy. This association appears common to antidepressants as a class since 
consistent results were also obtained when substituting SRI use with bupropion, a non-
serotonergic antidepressant. Furthermore, the risk associated with antidepressant use 
appears to result from a chronic, delayed process, rather than from an acute reaction, as 
the effect size is attenuated when evaluating SRI exposure and all-cause mortality 
during discrete 6-month epochs. Exposure to an SRI did not appear to significantly affect 
possible seizure-related death though the analyses were limited by few outcomes.  
 
Likely, the elevated risk of all-cause mortality related to SRI use is secondary to 
unmeasured clinical factors inherently associated with antidepressant use rather than 
through a direct drug effect. The sub-analysis evaluating the risk over immediate 6- 
month intervals following drug prescription demonstrated an attenuated, rather than 
enhanced, risk and the overall effect failed to reach significance in the general 
population. This is contrary to what would be expected if antidepressants were 
mechanistically responsible for premature death. Interestingly, these results are 
consistent with a prior large prospective study that linked antidepressant use with an 
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increased risk of sudden cardiac death over and above that conferred by depression 
alone25. Likewise, the protective effect of female sex was anticipated prior to the 
study26. 
 
The large statistical power conferred by CALIBER is one of the benefits of this platform. 
A randomised controlled trial of SRI use in epilepsy is impractical due to the attendant 
sample size. Assuming a risk of sudden death of 0.1% in an epilepsy population, with an 
α = 0.05 and a β = 0.2, one would require over 100,000 patients for a well-powered RCT. 
Thus, small trials will inevitably lead to imprecise estimates that are of minimal clinical 
utility. Hence, large linked data such as these are useful for addressing potentially small, 
but clinically meaningful, associations. An additional strength is the use of a previously 
published electronic health records case definition for epilepsy that is 92% accurate for 
paediatric epilepsy15. This definition is anticipated to perform equally well in adult 
populations; an assertion that is corroborated by the fact that the proportion of patients 
meeting our case definition for epilepsy appears similar to that in the general UK 
population (0.6%) thus providing face validity27. Comparing the consistency between 
observed and expected incidence rates and prevalence proportions is a common means 
of validating cases derived from electronic health records16. Requiring two codes for an 
SRI or bupropion on separate days enhanced the chances of an enduring prescription. It 
is not uncommon for antidepressants to be discontinued after a single prescription, 
often due to adverse effects, and therefore we imposed a stricter, more conservative, 
definition of exposure. However, irrespective of adherence, our results indicate that the 
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very need for two SRI prescriptions is associated with an elevated risk of all-cause 
mortality in both those with and those without epilepsy. We treated exposure to an SRI 
or bupropion as a time varying covariate in the primary analysis in order to minimise the 
risk of immortal time bias28. Finally, the secondary analysis (in which we stratified 
follow-up into discrete 6-month epochs) allowed us to further explore the immediate 
relationship between antidepressant exposure and mortality.  
 
Despite this, the results are subject to certain limitations. Misclassification bias may 
exist from the case definition for epilepsy. Although it is 92% accurate15, it was not 
designed for adults and we cannot exclude false positive diagnoses of epilepsy. This bias 
is expected to be non-differential in nature, though, thus diluting the magnitude of the 
overall estimate. Furthermore, there may be incomplete adjusting for depression status. 
Psychiatric symptoms and disorders are known to be under-ascertained in large 
population-based records such as administrative data29 and we were unable to control 
for conditions other than depression (e.g. bipolar disorder, schizophrenia).  However, 
we were able to use a previously published case definition of depression designed for 
the CALIBER database17, and it was reassuring to note that 72% of the active seizure 
group and 74% of the control group who were exposed to two or more SRI prescriptions 
had a corresponding code for past or current depression. Further reassurance is 
provided by the fact that the demographic differences between those exposed and 
unexposed to SRIs (Table 1) differed in directions anticipated by clinical experience (e.g. 
higher rates of depression, comorbidities, and lower socioecomonic status). 
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Unmeasured confounders are always an issue in non-randomised studies. For instance, 
worse IMD was an independent risk factor for death. This could partially relate to 
medication non-adherence30 while lower socioeconomic status has been linked to both 
depression and early mortality31. There is minimal chance of misclassification of all-
cause mortality. However, the fidelity of coding for cause-specific death may not 
entirely be accurate. In particular, seizure-related death may be inaccurately or simply 
under-coded32. In order to compensate for this, we expanded our definition of possible 
seizure-related death to include unknown/unspecified death and sudden death. 
Although this may increase the number of false positive seizure deaths, and could have 
diluted the effect size, the overall number of outcomes (n=151) was still low leading to 
an imprecise result. Hence, even in this large cohort, the potential effect of SRI use on 
seizure-specific mortality may be obscured by random error. Finally, we were unable to 
precisely determine whether there was a differential effect between antidepressant 
classes on possible seizure-related mortality in patients with epilepsy due to the low 
numbers exposed to bupropion. This almost certainly relates to the reluctance to use 
this medication in those with epilepsy due to its propensity to lower the seizure 
threshold33.  
 
Ultimately, analyses such as these are hypothesis generating and help inform future 
endeavours. This study cannot be used to establish a cause-effect relationship due to 
the intrinsic study design and source of data. Prospective studies are required to 
establish temporality. Furthermore, we cannot ensure adherence to SRIs or bupropion, 
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cannot ensure the prescriptions were filled, and cannot determine the daily dose for 
each patient. Thus, it is not possible to comment on a biological gradient. Additional 
studies replicating these results would also be required to meet causal criteria. Finally, 
although intriguing, it is hard to argue for biological plausibility of direct death related to 
antidepressant use. Rather, it is more credible that antidepressants function as a marker 
for an underlying biological process that is not controlled for even when adjusting for 
age, sex, CCI attribution of comorbidities, and social deprivation according to the IMD.  
 
This study provides important data that are directly applicable to both clinical practice 
and future research. Our results indicate that patients requiring multiple antidepressant 
prescriptions, even those without epilepsy, need to be followed closely as they 
represent a vulnerable population at increased risk of premature death. Vigilance may 
be required even for those who are seizure-free since it could potentially have a 
beneficial effect on all-cause mortality. Significantly, SRI was not related to seizure-
related mortality, thus further alleviating fears that SRI use may be detrimental for 
seizures. However, the low number of possible seizure-specific outcomes and the 
attendant wide confidence intervals necessarily tempers any conclusion about a 
protective effect. Future research designed to further elaborate on this association is 
crucial. Finally, an RCT of SRIs for the prevention of seizure-related death in patients 
with epilepsy appears impractical. Using increasingly large, linked electronic health 
record datasets, or systematically collected clinical data from multicentre cohorts can 
offer a valuable solution to further our understanding of SRIs, mortality and prevention 
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of seizure-related deaths. By quadrupling the sample size, we can halve the 95% 
confidence intervals around the effect estimate. Hence, in order to obtain more precise 
measures of the overall effect of SRI use on possible seizure-related mortality, any 
future large, linked electronic and administrative health record datasets would require 
at least 65,000 patients with epilepsy. Therefore, concerted, multicentre efforts are 
required to address this critical issue.  
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Table 1. Demographic comparison between those exposed to an SRI medication (two 



















SRI unexposed P value 
n (%) 2178 (13%) 14,201 (87%) N/A 
Age (years; IQR) 43 (31-59) 44 (29-61) 0.19 
Female sex (n; %) 1333 (61%) 7277 (51%) <0.001 
Charlson comorbidity index (median; IQR) 4 (0-13) 0 (0-11) <0.001 
Depression (n; %) 1564 (72%) 3318 (23%) <0.001 
Past or current smoker (n; %) 1204 (59%) 5880 (46%) <0.001 
Diabetes mellitus (n; %) 259 (12%) 1003 (7%) <0.001 
Hypertension (n; %) 615 (28%) 2827 (20%) <0.001 
IMD (median; IQR) 19 (11-33) 17 (10-30) <0.001 
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Table 2. Hazard ratio for all-cause mortality according to receipt of a second serotonin 
reuptake inhibitor (SRI) prescription code in 16,379 patients with epilepsy. Use of SRI 
was treated as a time-varying covariate. 
 
  Hazard ratio 95%CI p-value 
SRI exposure 1.64 1.44-1.86 <0.001 
Age 1.06 1.06-1.07 <0.001 
Female sex 0.78 0.72-0.85 <0.001 
Depression 0.98 0.89-1.07 0.641 
CCI 0.99 0.99-1.00 0.420 
IMD 1.01 1.01-1.01 <0.001 
Depression is past or current depression 
Abbreviations: 95%CI = 95% confidence interval; CCI = Charlson comorbidity index; IMD = Index of 
Multiple Deprivation 
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Table 3. Hazard ratio for all-cause mortality according to receipt of a serotonin reuptake 
inhibitor (SRI) prescription code in 16,379 patients with epilepsy during discrete 6-
month epochs of follow-up. 
 
              6-month epochs 
  Hazard ratio 95%CI p-value 
SRI exposure 1.04 1.00-1.09 0.044 
Age 1.06 1.06-1.07 <0.001 
Female sex 0.76 0.70-0.83 <0.001 
Depression 1.06 0.96-1.16 0.208 
CCI 1.00 0.99-1.00 0.838 
IMD 1.01 1.01-1.01 <0.001 
Depression is past or current depression 
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Table 4. Hazard ratio for possible seizure-specific mortality according to receipt of a 
second serotonin reuptake inhibitor (SRI) prescription code in 16,379 patients with 
epilepsy using a cause specific Cox proportional hazards regression model. Use of SRI 
was treated as a time-varying covariate. 
 
  Hazard ratio 95%CI p-value 
SRI exposure 1.08 0.59-1.97 0.796 
Age 1.01 1.00-1.02 0.005 
Female sex 0.70 0.50-0.96 0.028 
Depression 0.81 0.55-1.20 0.300 
CCI 0.97 0.94-0.99 0.035 
IMD 1.01 0.99-1.02 0.145 
Depression is past or current depression 
Abbreviations: 95%CI = 95% confidence interval; CCI = Charlson comorbidity index; IMD = Index of 
Multiple Deprivation 
  




Figure 1. Nelson-Aalen cumulative hazard estimates curve for all-cause death in patients 
with active epilepsy stratified according to time-varying SRI status (patients were 
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